← Leaderboards
Elizabeth G McFarland
University Of Colorado Denver
$39,720
Attributed
$39,720
Total exposure
10
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$39,720 · 10
By mechanism
M01$39,720 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Robert Turner Schooley$73,100,957
- William H Redd$26,150,383
- Elizabeth Connick$17,363,459
- Ross M Kedl$19,713,912
- Jenna Demedis$863,785
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman Therapy EvaluationHuman SubjectDrug Screening /EvaluationHiv InfectionsPediatric AidsChild (0-11)Aids TherapyClinical Trial Phase IPharmacokineticsInfant Human (0-1 Year)Antiaids AgentHelper T LymphocyteCombination ChemotherapyPediatric PharmacologyProtease InhibitorAids VaccinesDosageVirus LoadNevirapineLamivudineMicroorganism Disease ChemotherapyChemopreventionDrug Tolerance
Grant awards (18)
ACTG 300--STUDY OF 3TC, ZDV AND DDI IN HIV INFECTED CHILDREN$0
M01 · FY2002 · RR
ACTG 219--PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2002 · RR
ACTG 326-- ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS$0
M01 · FY2002 · RR
ACTG 345 PHASE I/II STUDY OF RITONAVIR IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2002 · RR
ACTG#316--NEVIRAPINE FOR PREVENTION OF MATERNAL-FETAL TRANS. OF HIV$0
M01 · FY2002 · RR
PHASE I/II TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILD$0
M01 · FY2002 · RR
ACTG 254--ATOVAQUONE/AZITHROMYCIN VS TMP/SMX TO PREVENT BACTERIAL INFECTION$0
M01 · FY2002 · RR
ACTG 366-- NOVEL ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL EXP CHILD$0
M01 · FY2002 · RR
ACTG 230--SAFETY AND IMMUNOGENICITY OF HIV 1 ENVELOPE ANTIGEN CANDIDATE VACCINES$19,860
M01 · FY2000 · RR
ACTG 273: HIVIG IN SLOWING DISEASE PROGRESSION IN HIV INFECTED CHILD$19,860
M01 · FY2000 · RR
ACTG 366-- NOVEL ANTIRETROVIRAL THERAPY IN ANTIRETROVIRAL EXP CHILD$0
M01 · FY2000 · RR
ACTG 326-- ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS$0
M01 · FY2000 · RR
ACTG 345 PHASE I/II STUDY OF RITONAVIR IN HIV INFECTED INFANTS AND CHILDREN$0
M01 · FY2000 · RR
ACTG#316--NEVIRAPINE FOR PREVENTION OF MATERNAL-FETAL TRANS. OF HIV$0
M01 · FY2000 · RR
PHASE I/II TRIAL OF RECOMBINANT INTERLEUKIN 2 IN SYMPTOMATIC HIV INFECTED CHILD$0
M01 · FY2000 · RR
ACTG 254--ATOVAQUONE/AZITHROMYCIN VS TMP/SMX TO PREVENT BACTERIAL INFECTION$0
M01 · FY2000 · RR
ACTG 300--STUDY OF 3TC, ZDV AND DDI IN HIV INFECTED CHILDREN$0
M01 · FY2000 · RR
ACTG 219--PEDIATRIC HIV LATE OUTCOMES PROTOCOL$0
M01 · FY2000 · RR